Optimal chemokine receptors for enhancing immune cell trafficking in adoptive cell therapy

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Immunologic research

• Publication date

  2025-01-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12026-024-09560-yPMID 39815137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expressing IL-15/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer.

  2023cited by this paper
• Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies

  2023cited by this paper
• Who wins the combat, CAR or TCR?

  2023cited by this paper
• Challenges and new technologies in adoptive cell therapy

  2023cited by this paper
• The Interplay between T Cells and Cancer: The Basis of Immunotherapy

  2023cited by this paper
• Harnessing the chemokine system to home CAR-T cells into solid tumors

  2022cited by this paper
• Chemokine Receptor Expression on T Cells Is Modulated by CAFs and Chemokines Affect the Spatial Distribution of T Cells in Pancreatic Tumors

  2022cited by this paper
• Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumors

  2022cited by this paper
• Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti‐Leukemia Efficacy of CAR‐T Cells via SOCE‐Calcineurin‐NFAT and Glycolysis Pathways

  2022cited by this paper
• Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming

  2021cited by this paper
• Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy

  2021cited by this paper
• CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells

  2021cited by this paper
• CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model

  2021cited by this paper
• Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)

  2021cited by this paper
• T cells armed with the C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

  2021cited by this paper
• Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model

  2021cited by this paper
• CAR T cells in solid tumors: challenges and opportunities

  2021cited by this paper
• CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer

  2021cited by this paper
• Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer

  2020cited by this paper
• Directing Traffic: How to Effectively Drive T Cells into Tumors.

  2020cited by this paper
• CXCR2‐modified CAR‐T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma

  2020cited by this paper
• Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

  2020cited by this paper
• CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4

  2020cited by this paper
• TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues

  2020cited by this paper
• CAR-T cell engineering with CCR6 exhibits superior anti-solid tumor efficacy.

  2020cited by this paper
• CXCL13/CXCR5 signaling axis in cancer.

  2019cited by this paper
• Identification of Differently Expressed Genes Associated With Prognosis and Growth in Colon Adenocarcinoma Based on Integrated Bioinformatics Analysis

  2019cited by this paper
• CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

  2019cited by this paper
• CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts

  2019cited by this paper
• CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond

  2019cited by this paper
• NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives

  2018cited by this paper
• Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice

  2018influential reference
• Adoptive cellular therapies: the current landscape

  2018cited by this paper
• Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model

  2018cited by this paper
• A comparison of per sample global scaling and per gene normalization methods for differential expression analysis of RNA-seq data

  2017cited by this paper
• Role of CXC group chemokines in lung cancer development and progression.

  2017cited by this paper
• Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer

  2017cited by this paper
• Prospects for gene-engineered T cell immunotherapy for solid cancers

  2016cited by this paper
• The basic principles of chimeric antigen receptor design.

  2013cited by this paper
• STAR: ultrafast universal RNA-seq aligner

  2013cited by this paper
• RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

  2011influential reference
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

  2006cited by this paper
• Ligand Selectivity and Affinity of Chemokine Receptor CXCR1

  2004cited by this paper
• Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor.

  2001cited by this paper
• B Cell–attracting Chemokine 1, a Human CXC Chemokine Expressed in Lymphoid Tissues, Selectively Attracts B Lymphocytes via BLR1/CXCR5

  1998cited by this paper
• A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1

  1998cited by this paper

• Redirecting engineered immune cells using G protein-coupled receptors in cancer therapy

  2026cites this paper